丁苯酞联合阿加曲班治疗急性脑梗死的效果分析

Effect analysis of butylphthalide combined with argatroban in the treatment of acute cerebral infarction

目的 分析急性脑梗死(ACI)采取阿加曲班联合丁苯酞治疗的效果。方法 88例ACI患者,随机分为观察组和对照组,各44例。观察组应用丁苯酞+阿加曲班治疗,对照组应用丁苯酞治疗。对比两组患者神经功能指标[脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、星形胶质原性蛋白(S100-β)]、基质细胞衍生因子-1(SDF-1)、视锥蛋白样蛋白-1(VILIP-1)、炎症因子[白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)]、治疗效果、不良反应发生情况。结果 治疗后,观察组BDNF(5.58±0.37)ng/ml高于对照组的(4.35±0.58)ng/ml,NSE(20.37±6.48)μg/L、S100-β(0.28±0.07)μg/L低于对照组的(33.71±8.62)、(0.41±0.12)μg/L,组间对比均有统计学意义(P<0.05)。治疗后,观察组SDF-1(3053.47±182.56)pg/ml高于对照组的(2863.52±142.60)pg/ml,VILIP-1(542.26±91.31)pg/ml低于对照组的(582.73±78.65)pg/ml,组间对比均有统计学意义(P<0.05)。治疗后,观察组IL-6、TNF-α、hs-CRP分别为(13.74±2.24)ng/L、(24.17±5.71)ng/L、(6.40±1.51)mg/L,均低于对照组的(17.62±2.53)ng/L、(30.62±4.27)ng/L、(8.37±1.28)mg/L,组间对比具有统计学意义(P<0.05)。观察组治疗总有效率为95.45%,高于对照组的81.82%,组间对比具有统计学意义(P<0.05)。观察组不良反应发生率为9.09%,对照组不良反应发生率为13.64%,组间对比无统计学意义(P>0.05)。结论 丁苯酞联合阿加曲班治疗ACI可有效改善患者神经功能指标及炎症因子水平,提高疗效。

Objective To analyze the effect of butylphthalide combined with argatroban in the treatment of acute cerebral infarction(ACI).Methods 88 patients with ACI were randomly divided into an observation group and a control group,with 44 cases in each group.The observation group was treated with butylphthalide + argatroban,and the control group was treated with butylphthalide.Both groups were compared in terms of neurological function indexes [brain-derived neurotrophic factor(BDNF),neuron-specific enolase(NSE),astroglia-derived protein(S100-β)],stromal cell-derived factor-1(SDF-1),visinin-like protein-1(VILIP-1),inflammatory factors [interleukin-6(IL-6)],and tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP)],treatment effect,and occurrence of adverse reactions.Results After treatment,the observation group had higher BDNF of(5.58±0.37) ng/ml than(4.35±0.58) ng/ml in the control group,and lower NSE of(20.37±6.48) μg/L and S100-β of(0.28±0.07) μg/L than(33.71±8.62) and(0.41±0.12) μg/L in the control group.There was statistical significance between the two groups(P<0.05).After treatment,the observation group had higher SDF-1 of(3053.47±182.56) pg/ml than(2863.52±142.60) pg/ml in the control group,and lower VILIP-1 of(542.26±91.31) pg/ml than(582.73±78.65) pg/ml in the control group.There was statistical significance between the two groups(P<0.05).After treatment,IL-6,TNF-α and hs-CRP in the observation group were(13.74±2.24) ng/L,(24.17±5.71) ng/L and(6.40±1.51) mg/L,which were lower than(17.62±2.53) ng/L,(30.62±4.27) ng/L and(8.37±1.28) mg/L in the control group,and the comparison between groups was statistically significant(P<0.05).The total effective rate of the observation group was 95.45%,which was higher than 81.82% of the control group,and the comparison between the two group was statistically significant(P<0.05).The incidence of adverse reactions was 9.09% in the observation group and 13.64% in the control group,with no statistical significance between the two groups(P>0.05).Conclusion The combination of butylphthalide and argatroban in the treatment of ACI can effectively improve the neurological indicators and the level of inflammatory factors of patients,and improve the efficacy.